CORDIS
EU research results

CORDIS

English EN

Delivering ECMO-BIOMARKER – a ground-breaking ICT-enabled ECMO Biomarker system providing clinicians with bedside decision support for better care and reduced costs of severe ICU patients

Objective

One out of ten ICU respiratory patients are characterised as being “severe”, with a lung function of less than 20% due to acute respiratory failure. This group are often referred to ECMO (Extra Corporal Membrane Oxygenation) treatment, in which the patient’s blood is oxygenized by an external machine, costing European healthcare centres €26Bn+ annually. The problem is, due to the rudimentary tools that ICU doctors use to diagnose these patients, 20% of all ECMO patients should not have been treated with ECMO and instead could have stayed in conventional intensive ventilation care. Industry partner Mermaid Care aims to solve this problem with ECMO-BIOMARKER – the world’s first biomarker-based companion diagnostic tool for severe lung injury patients. ECMO-BIOMARKER will potentially reduce ECMO referrals by 10-20%, slashing costs for the average European ECMO centre by an estimated €23-48M annually. Based on clinically predictive biomarker measurements, ECMO-BIOMARKER uses novel algorithms and physiological model to deliver accurate diagnosis recommendations for each patient, bedside and in less than 2 minutes. This ICT-approach changes workflow and empowers low-skilled ICU doctors to perform ECMO diagnosis. In the proposed action, ECMO-BIOMARKER value proposition (reduction in ECMO patients) will be clinically documented together with 4 world-leading partners in the field of ICU management and ECMO treatment: 3 clinical research partners – Imperial College London with the clinical site Royal Brompton Hospital (UK), Medical University of Vienna (AT) and Centre Hospitalier Universitaire de Clermont-Ferrand (FR) – and research partner Aalborg University (DK). After the project, ECMO-BIOMARKER is launched on the EU market, allowing European hospitals to cut ICU costs and improve patient quality of care. This project will allow Mermaid Care to reach sales of €160M in 2025 and hire 30 new employees. The innovation is based on +16 years of research and 10 patents.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

MERMAID CARE AS

Address

Hedelund 1
9400 Norresundby

Denmark

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 651 475

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 625 312,50

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 164 248,75

CENTRE HOSPITALIER UNIVERSITAIRE DE CLERMONT-FERRAND

France

EU Contribution

€ 215 155

AALBORG UNIVERSITET

Denmark

EU Contribution

€ 195 000

Project information

Grant agreement ID: 853850

Status

Ongoing project

  • Start date

    1 April 2019

  • End date

    31 March 2021

Funded under:

H2020-EU.3.

H2020-EU.2.1.

  • Overall budget:

    € 3 558 966,25

  • EU contribution

    € 2 851 191,25

Coordinated by:

MERMAID CARE AS

Denmark